Landscape Capital Management L.L.C. Takes Position in Medpace Holdings, Inc. $MEDP

Landscape Capital Management L.L.C. acquired a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP) during the 4th quarter, Holdings Channel.com reports. The firm acquired 3,174 shares of the company’s stock, valued at approximately $1,783,000.

Several other institutional investors and hedge funds have also made changes to their positions in MEDP. Dorsey Wright & Associates purchased a new position in Medpace during the third quarter worth about $5,082,000. Capital Fund Management S.A. lifted its position in Medpace by 129.5% during the third quarter. Capital Fund Management S.A. now owns 32,412 shares of the company’s stock worth $16,665,000 after buying an additional 18,287 shares during the period. Victory Capital Management Inc. lifted its position in Medpace by 32.9% during the third quarter. Victory Capital Management Inc. now owns 30,539 shares of the company’s stock worth $15,702,000 after buying an additional 7,565 shares during the period. Fisher Asset Management LLC lifted its position in Medpace by 9.9% during the third quarter. Fisher Asset Management LLC now owns 137,746 shares of the company’s stock worth $70,824,000 after buying an additional 12,399 shares during the period. Finally, Intech Investment Management LLC lifted its position in Medpace by 31.9% during the third quarter. Intech Investment Management LLC now owns 18,395 shares of the company’s stock worth $9,458,000 after buying an additional 4,448 shares during the period. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Medpace Price Performance

Shares of NASDAQ:MEDP opened at $467.50 on Tuesday. The firm has a market capitalization of $13.35 billion, a PE ratio of 29.38, a P/E/G ratio of 2.37 and a beta of 1.18. The business has a 50-day moving average of $455.81 and a two-hundred day moving average of $502.82. Medpace Holdings, Inc. has a 12 month low of $294.07 and a 12 month high of $628.92.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Wednesday, April 22nd. The company reported $4.28 EPS for the quarter, topping the consensus estimate of $3.74 by $0.54. The company had revenue of $706.60 million during the quarter, compared to analyst estimates of $697.82 million. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The firm’s revenue was up 26.5% on a year-over-year basis. During the same period in the prior year, the firm posted $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, research analysts anticipate that Medpace Holdings, Inc. will post 17.04 earnings per share for the current year.

Insider Activity

In other news, General Counsel Stephen P. Ewald sold 16,349 shares of the stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $450.00, for a total value of $7,357,050.00. Following the completion of the sale, the general counsel owned 20,343 shares in the company, valued at approximately $9,154,350. This trade represents a 44.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 20.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on MEDP shares. Barclays reduced their target price on Medpace from $500.00 to $450.00 and set an “equal weight” rating on the stock in a research report on Friday, April 24th. Wall Street Zen downgraded Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Robert W. Baird reduced their target price on Medpace from $565.00 to $477.00 and set an “outperform” rating on the stock in a research report on Friday, April 24th. BMO Capital Markets reduced their target price on Medpace from $460.00 to $400.00 and set a “market perform” rating on the stock in a research report on Friday, April 24th. Finally, TD Cowen upgraded Medpace from a “sell” rating to a “hold” rating and reduced their target price for the stock from $462.00 to $419.00 in a research report on Wednesday, February 18th. Four analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Medpace currently has an average rating of “Hold” and an average price target of $467.08.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.